GHRP-2 Side Effects

Reported GHRP-2 side effects

Common (dose-dependent) Increased appetite / hunger — GHRP-2 is a ghrelin-receptor agonist, and ghrelin is the body's primary hunger signal. Expect measurable appetite stimulation starting ~30 minutes post-injection and peaking at 1-2 hours. Beneficial in caloric surplus phases; problematic in deficit phases. Transient cortisol elevation — +15-25% above baseline in the 60-90 min post-injection window. Usually clinically trivial in healthy users but relevant in users with HPA axis dysregulation, adrenal insufficiency, or stress-driven cortisol issues. Modest prolactin elevation — usually not clinically meaningful but relevant in users with baseline prolactin concerns or prolactin-sensitive pathologies. Injection site reactions — mild erythema or transient itching at SC site; site rotation minimizes. Flushing — warm, pink flush in face/neck post-injection, fading within 15-30 minutes. Less Common Mild fluid retention — particularly in first 2-3 weeks of daily use; usually self-limiting. Vivid dreams — secondary to improved slow-wave sleep when dosed at bedtime. Transient insulin sensitivity reduction — GH-axis stimulation modestly reduces insulin sensitivity; monitor HbA1c and fasting glucose in extended use. Headache — mild, typically responsive to hydration. Nausea — uncommon at SC doses; more common with high IV boluses. Rare Significant hypotension — primarily with IV administration; SC route rarely produces meaningful BP effects. Hypersensitivity reactions — rare local or systemic allergic response. Paresthesia or scalp tingling — transient, benign. Dysgeusia — metallic or unusual taste immediately post-injection. Cumulative with Long-term Use Insulin resistance — sustained daily dosing over months can modestly reduce insulin sensitivity. Monitor HbA1c and fasting insulin quarterly. Receptor desensitization — unlike GHRH analogs which retain pituitary responsiveness well, chronic high-dose GHS can produce measurable GHS-R1a tachyphylaxis. Cycling protocols (5 on / 2 off, or 8 weeks on / 2 weeks off) help maintain responsiveness. HPA axis adaptation — persistent low-grade cortisol elevation over months could theoretically contribute to HPA dysregulation in susceptible users. Periodic ACTH/cortisol monitoring in chronic protocols is sensible. Theoretical Long-term Concerns As with all GH-axis interventions, the IGF-1 elevation produced by GHRP-2 raises a theoretical concern around chronic supraphysiologic mitogenic signaling and cancer risk. No causal link has been demonstrated in trials, but mechanistic plausibility supports conservative dosing, periodic IGF-1 monitoring, and avoidance in users with active malignancy or strong family history of hormonally-responsive cancers. Signs You Are Overdosing Persistent joint discomfort or peripheral edema Carpal tunnel-like symptoms Persistent elevated fasting glucose Unexpected weight gain beyond what caloric intake accounts for Sleep apnea worsening Any of these warrant dose reduction or discontinuation.

When to continue, reduce, or stop GHRP-2

GHRP-2 contraindications

GHRP-2 is contraindicated or requires caution in: Active malignancy — particularly hormone-responsive cancers (breast, prostate); elevated IGF-1 may promote tumor growth Strong family history of GH-axis sensitive cancers — specialist supervision required Pregnancy and lactation — no established safety data; avoid Known hypersensitivity to GHRP-2, related hexapeptides, or any excipient Severe untreated obstructive sleep apnea — theoretical airway soft-tissue concern Acute critical illness — GH-axis stimulation inappropriate during sepsis, post-surgical recovery, multiple trauma, respiratory failure Diabetic ketoacidosis or severe uncontrolled diabetes — resolve metabolic state first Active proliferative retinopathy — relative contraindication Hypothalamic-pituitary disease with adrenal insufficiency — the residual cortisol effect may be unreliable; specialist supervision required Prolactinoma or hyperprolactinemia — the modest prolactin elevation could complicate management Relative cautions (monitor closely): Borderline fasting glucose or HbA1c — GH-axis effects can tip toward insulin resistance Cushing's syndrome or baseline elevated cortisol — GHRP-2 adds to HPA axis load Anxiety or HPA axis dysregulation — the cortisol elevation, while modest, may be poorly tolerated Strong family history of colon polyps — baseline colonoscopy before starting, surveillance per GI guidelines Concurrent glucocorticoid therapy — GH-axis stimulation is less effective under pharmacologic steroid Drug interactions: Glucocorticoids: Pharmacodynamic interference; reduced GH response Opiates/opioids: Can augment the cortisol and prolactin effects of GHRP-2; monitor Thyroid hormone replacement: GH-axis changes can modify thyroid needs; monitor TSH if using chronically Exogenous GH: Pharmacologically counterproductive; the combination is pointless Discontinuation triggers: Persistent joint pain, carpal tunnel symptoms, or peripheral edema (suggesting IGF-1 is too high) Persistent fasting glucose elevation beyond 110 mg/dL Any signs of cushingoid body composition change (buffalo hump, moon face, central obesity beyond baseline) Worsening sleep apnea New or changing pigmented lesions (unrelated to GHRP-2 but always a stop-and-evaluate signal in any peptide protocol) Any cardiovascular symptoms

Why vendor quality drives GHRP-2 side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

GHRP-2 side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .